These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9856996)

  • 61. In vivo rabbit acute model tests of polyurethane catheters coated with a novel antithrombin-heparin covalent complex.
    Du YJ; Klement P; Berry LR; Tressel P; Chan AK
    Thromb Haemost; 2005 Aug; 94(2):366-72. PubMed ID: 16113827
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity.
    Grootenhuis PD; Westerduin P; Meuleman D; Petitou M; van Boeckel CA
    Nat Struct Biol; 1995 Sep; 2(9):736-9. PubMed ID: 7552742
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mechanism of inactivation of trypsin by antithrombin.
    Danielsson A; Björk I
    Biochem J; 1982 Oct; 207(1):21-8. PubMed ID: 6817749
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1979 Sep; 586(3):584-93. PubMed ID: 476156
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Mechanism of thrombin inactivation by immobilized heparin.
    Byun Y; Jacobs HA; Kim SW
    J Biomed Mater Res; 1996 Apr; 30(4):423-7. PubMed ID: 8847350
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis.
    Raja SM; Chhablani N; Swanson R; Thompson E; Laffan M; Lane DA; Olson ST
    J Biol Chem; 2003 Apr; 278(16):13688-95. PubMed ID: 12591924
    [TBL] [Abstract][Full Text] [Related]  

  • 68. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding.
    Peterson CB; Morgan WT; Blackburn MN
    J Biol Chem; 1987 Jun; 262(16):7567-74. PubMed ID: 3584128
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.
    Buchanan MR; Brister SJ
    Thromb Res; 2000 Sep; 99(6):603-12. PubMed ID: 10974347
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A comparative study on the mechanism of the anticoagulant action of mollusc and mammalian heparins.
    Paiva JF; Santos EA; Jeske W; Fareed J; Nader HB; Dietrich CP
    Comp Biochem Physiol A Physiol; 1995 Jul; 111(3):495-9. PubMed ID: 7614042
    [TBL] [Abstract][Full Text] [Related]  

  • 72. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
    Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
    Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
    [TBL] [Abstract][Full Text] [Related]  

  • 73. In vitro and in vivo characterization of a reversible synthetic heparin analog.
    Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
    Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Enhancement of heparin cofactor II anticoagulant activity.
    Bauman SJ; Church FC
    J Biol Chem; 1999 Dec; 274(49):34556-65. PubMed ID: 10574918
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin.
    Li W; Johnson DJ; Esmon CT; Huntington JA
    Nat Struct Mol Biol; 2004 Sep; 11(9):857-62. PubMed ID: 15311269
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Measurement of the heparin enhanced-antithrombin III/thrombin reaction rate in the presence of synthetic substrate.
    Griffith MJ
    Thromb Res; 1982 Feb; 25(3):245-53. PubMed ID: 7064134
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.
    Rashid Q; Singh P; Abid M; Jairajpuri MA
    J Thromb Thrombolysis; 2012 Aug; 34(2):251-9. PubMed ID: 22453684
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Linear diffusion of thrombin and factor Xa along the heparin molecule explains the effects of extended heparin chain lengths.
    Wagenvoord R; Al Dieri R; van Dedem G; Béguin S; Hemker HC
    Thromb Res; 2008; 122(2):237-45. PubMed ID: 18045667
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The Choay domain -- the structure responsible for the anticoagulant action of heparins].
    Hemker HC; al Dieri R; Wagenvoord R; Béguin S
    Bull Acad Natl Med; 2003; 187(1):59-66; discussion 66-7. PubMed ID: 14556454
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.
    Olson ST; Swanson R; Petitou M
    Blood; 2012 Mar; 119(10):2187-95. PubMed ID: 22144183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.